BOTHELL, Wash. & OSAKA, Japan-- --Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today announced that patients with Hodgkin lymphoma who received ADCETRIS as consolidation therapy immediately following an autologous stem cell transplantation lived significantly longer without disease progression compared to patients who received placebo.
http://ift.tt/1nAEh0Q
http://ift.tt/1nAEh0Q
No comments:
Post a Comment